Targeting mTORC1 is an effective strategy to inhibit meningioma cell tumorigenicity

Authors :: Pachow, D
Kirches, E
Mawrin, C
Source :: 57th Annual Meeting of the German Society for Neuropathology and Neuroanatomy (DGNN); 20120912-20120915; Erlangen; DOC12dgnnPP3.10 /20120911/
Publication Year :: 2012
Publisher :: German Medical Science GMS Publishing House, 2012.
Abstract: Background: The mammalian target of Rapamycin (mTOR) regulates cell growth, proliferation, and motility. Since enhanced activity is frequently observed in malignant cells, mTORC1 inhibition has become an attractive strategy to treat cancer. Rapamycin analogues, like temsirolimus and everolimus, have[for full text, please go to the a.m. URL]<br />57th Annual Meeting of the German Society for Neuropathology and Neuroanatomy (DGNN)

Language :: English
Database :: OpenAIRE
Journal :: 57th Annual Meeting of the German Society for Neuropathology and Neuroanatomy (DGNN); 20120912-20120915; Erlangen; DOC12dgnnPP3.10 /20120911/
Accession number :: edsair.doi.dedup.....16de733eb210c5c40b4bf3c44b7680ff
Full Text :: https://doi.org/10.3205/12dgnn054

Full Text Access

Tools